Literature DB >> 3932074

Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.

S Sakoda, T Suzuki, S Higa, M Ueji, S Kishimoto, M Matsumoto, S Yoneda.   

Abstract

Orthostatic hypotension in a patient with Shy-Drager syndrome was treated for 6 months with oral DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS). Adrenergic function was evaluated before and during treatment by measurements of changes in blood pressure and plasma norepinephrine on head-up tilting and by the response of blood pressure to the Valsalva maneuver and infused norepinephrine. After the patient received DL-threo-DOPS, the fall in his mean arterial blood pressure on head-up tilting was reduced and he had no syncope when standing. When peripheral decarboxylase inhibitor was combined with DL-threo-DOPS, the same beneficial effect on orthostatic hypotension was observed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932074     DOI: 10.1159/000115820

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  5 in total

Review 1.  Otoneurological manifestations of the Shy-Drager syndrome.

Authors:  N Ohashi; H Nakagawa; K Kanda; K Mizukoshi
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

2.  Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

3.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

4.  Memory effect of DL-threo-3,4-dihydroxyphenylserine (DOPS) in human Korsakoff's disease.

Authors:  P J Langlais; R G Mair; P J Whalen; W McCourt; W J McEntee
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 5.  Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms.

Authors:  Sabine Eschlböck; Gregor Wenning; Alessandra Fanciulli
Journal:  J Neural Transm (Vienna)       Date:  2017-10-22       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.